Why the study?
The study aimed to assess primary treatment outcomes and complications according to the type of medication used in Iranian pulmonary embolism patients after hospital discharge.
In a retrospective case series of Iranian patients with pulmonary embolism, mortality was strongly driven by underlying conditions such as cancer and hypertension, with no significant differences in outcomes observed between different anticoagulant therapies.
Findings should not change anticoagulant selection in PE; cancer and hypertension associations remain hypothesis-generating.
Background: The primary cause of mortality in pulmonary embolism (PE) is believed to be the lack of emergency treatment. Objectives: This study aimed to assess the outcomes of primary treatment and evaluate complications based on the type of medication used in Iranian PE patients after hospital discharge. Methods: This retrospective study was conducted on 108 PE patients admitted to Shohada Tajrish Hospital, Tehran, Iran, during 2018 - 2019. Clinical manifestations, treatment methods, drug-related complications, and prognosis were analyzed within six months post-discharge. Results: A significant association was observed between underlying diseases and the mortality rate (P < 0.05). The frequency of prescribed medications in PE patients was as follows: 60% for rivaroxaban, 9% for apixaban, 14% for warfarin, and 17.5% for enoxaparin. No significant correlation was found between death, bleeding, and the type of drug used. Conclusions: The increased mortality rate in PE patients is strongly associated with underlying conditions, such as cancer. The use of anticoagulants significantly reduces mortality rates in PE patients.
No takes yet. Share an insight, caveat, or question.
Mohammadi et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: